XOMA Corporation
NASDAQ:XOMAP · NASDAQ Global Market
+$0.02 today
Vol 0.00M · Avg 0.00M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:XOMAP · Revenue to Net Income
Key Ratios
Analysis
$27.4M of revenue converted into $33.8M of net income for the selected period. Gross margin is 96.9% and net margin is 793.4%, showing how much revenue survives after costs and taxes. EPS is $1.65, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $52.1M +83.1% | $28.5M +498.7% | $4.8M -21.1% | $6.0M -84.2% | $38.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $3.0M +1337.4% | $206.0K +44.1% | $143.0K -47.8% | $274.0K +60.2% | $171.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $49.2M +73.9% | $28.3M +512.8% | $4.6M -19.8% | $5.8M -84.9% | $38.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 94.3% -5.0pp | 99.3% +2.3pp | 97.0% +1.5pp | 95.5% -4.1pp | 99.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $1.7M -40.5% | $2.9M +1910.5% | $143.0K -6.5% | $153.0K -10.5% | $171.0K | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $36.1M +4.7% | $34.5M +26.8% | $27.2M +17.2% | $23.2M +13.3% | $20.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $37.8M -44.6% | $68.3M +46.9% | $46.5M +100.6% | $23.2M +13.2% | $20.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.0M +1275.9% | $216.0K -76.0% | $900.0K +228.5% | $274.0K +3814.3% | $7.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | $47.8M +981.8% | -$5.4M +76.0% | -$22.6M -33.9% | -$16.8M -203.0% | $16.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 91.7% +110.7pp | -19.0% +455.2pp | -474.2% -194.7pp | -279.5% -322.4pp | 42.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | $11.4M +128.5% | -$40.0M +4.5% | -$41.8M -140.3% | -$17.4M -199.3% | $17.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 21.8% +162.2pp | -140.3% +739.2pp | -879.5% -590.6pp | -288.9% -334.9pp | 45.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.5M | $0 | $0 -100.0% | $694.0K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $13.0M -5.8% | $13.8M +2332.3% | $569.0K | $0 -100.0% | $461.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $20.4M -0.3% | $20.5M +1915.4% | $1.0M +244.7% | $295.0K +118.0% | -$1.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $31.8M +263.3% | -$19.5M +52.3% | -$40.8M -138.5% | -$17.1M -207.7% | $15.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 61.0% +129.4pp | -68.4% +789.8pp | -858.2% -574.1pp | -284.0% -325.7pp | 41.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $103.0K +101.8% | -$5.7M | $0 +100.0% | -$15.0K -116.5% | $91.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $31.7M +329.4% | -$13.8M +66.2% | -$40.8M -138.7% | -$17.1M -208.3% | $15.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | 60.8% +109.3pp | -48.5% +809.6pp | -858.2% -574.4pp | -283.8% -325.2pp | 41.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +192.7% | -$2 +59.2% | -$4 -104.0% | -$2 -387.0% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +188.5% | -$2 +59.2% | -$4 -104.0% | -$2 -404.6% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $18.0M +53.7% | $11.7M +2.0% | $11.5M +0.5% | $11.4M +1.1% | $11.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $18.0M +53.7% | $11.7M +2.0% | $11.5M +0.5% | $11.4M -6.4% | $12.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tectonic Therapeutic, Inc.
NASDAQ:TECX
$562.30M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$350.28M
Amarin Corporation plc
NASDAQ:AMRN
$330.93M
Silence Therapeutics plc
NASDAQ:SLN
$327.57M
Cellectis S.A.
NASDAQ:CLLS
$307.28M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$305.94M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$294.56M
AC Immune S.A.
NASDAQ:ACIU
$241.71M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$117.32M
Genelux Corporation
NASDAQ:GNLX
$110.03M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does XOMAP generate?
XOMA Corporation (XOMAP) reported $52.15M of revenue in fiscal 2025.
Is XOMAP profitable?
XOMA Corporation (XOMAP) reported $31.71M of net income, with a net margin of 60.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.